Recent studies have shown that the cell type specificity of eRNA (such as CD8+ T cells) contributes to the understanding of heterogeneity within tumors the heterogeneity within the tumor, which better explains the cancer phenotype than mRNA, and eRNA may regulate the immune checkpoint of melanoma patients treated with anti-PD-1 [63]. The gene discussed is CD8A; the disease is melanoma.